Two marketed clove buds were subjected to crude drug standardization by sampling from retail packages as per WHO recommended guidelines. The marketed clove products viz. brand-A and brand-B were standardized comparatively for various parameters like, powder fineness, foreign matter, ash values, volatile oil content, bitterness value, swelling index, foaming index, heavy metals, Mycological examinations, spectral analysis, qualification of Eugenol by TLC and quantification by HPLC. The results were compared with individual monograph limits specified in Indian Pharmacopoeia. The volatile oil content were estimated by Azeotropic distillation and were found to be 1.5ml and 1.2ml/10gms respectively for brand-A and brand-B against the limit 1.5 to 2.1ml. The UV spectra and ATR-IR spectra of both volatile oils were identical with the finger print of standard Eugenol oil. The foreign matter and ash value for brand-A and brand-B were 1.49%, 5.8% and 3.79%, 6%, respectively and brand-B doesn’t complies with the specified monograph limits (NMT 3%) for foreign matter. The Eugenol content in the volatile oil was quantitated by RP-HPLC method and was found to be 93.3.1% and 74.6% respectively for brand-A and brand-B against the standard monograph limit of 85-95%. It was noted that the brand-A was found to be superior quality and whilst brand-B disqualifies in standardization parameters such as Foreign matter, Volatile matter and Eugenol content. World Health Organization has emphasized the need to ensure quality control of medicinal plant products by applying suitable parameters and standards. In order to overcome certain inevitable shortcoming of the Pharmacopoeial monograph and other quality control measures, the present study explores the possible parameters of crude drug standardization for marketed clove buds with special reference to their quality and purity as per WHO guidelines.